CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues:
Total revenue	$ 9,282	$ 19,018	$ 13,679	$ 21,999
Costs and expenses:
Cost of revenue	848	923	2,698	3,146
Research and development	23,876	23,656	71,738	56,741
General and administrative	7,091	5,813	24,198	17,987
Licensing	7,344	7,300	8,955	7,300
Revaluation of contingent consideration	1,700	2,200	(600)	(2,400)
Total costs and expenses	40,859	39,892	106,989	82,774
Loss from operations	(31,577)	(20,874)	(93,310)	(60,775)
Other income, net	2,316	922	6,320	1,502
Net loss	$ (29,261)	$ (19,952)	$ (86,990)	$ (59,273)
Net loss per share, basic	$ (0.41)	$ (0.30)	$ (1.25)	$ (0.92)
Net loss per share, diluted	$ (0.41)	$ (0.30)	$ (1.25)	$ (0.92)
Weighted average common shares outstanding, basic	70,807,934	66,675,337	69,452,495	64,718,008
Weighted average common shares outstanding, diluted	70,807,934	66,675,337	69,452,495	64,718,008
Other comprehensive loss:
Unrealized loss on marketable securities, net of tax of $0	$ (18)	$ (139)	$ (232)	$ (1,241)
Total other comprehensive loss	(18)	(139)	(232)	(1,241)
Comprehensive loss	(29,279)	(20,091)	(87,222)	(60,514)
Contract research
Revenues:
Total revenue	705	1,090	2,469	3,529
Licensing
Revenues:
Total revenue	$ 8,577	17,898	$ 11,210	18,378
Other
Revenues:
Total revenue		$ 30		$ 92